In February 2023, a phase 1 trial at a single institution found that it was safe and possible for people with heavily pretreated large B-cell lymphoma (LBCL) to use CD22-directed chimeric antigen rec...
large-b-cell-lymphoma
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prio...
large-b-cell-lymphoma
July 2022: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been approved by the Food and Drug Administration for adult patients with large B-cell lymphoma (LBCL) who have refractor...
large-b-cell-lymphoma
China's National Medical Products Administration (NMPA) has approved JW Therapeutics' investigational new drug (IND) application for a key clinical trial of Carteyva (relmacabtagene autoleucel) in peo...
large-b-cell-lymphoma
August 2021: The FDA granted loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, accelerated approval for adult patients with relapsed...
large-b-cell-lymphoma